European Psychiatry

Background Escalating mental health service demands have created a need to better identify young people most likely to require continued support from mental health services at the transition between childhood and adulthood. Anxiety is the most common adolescent mental health condition, yet its clinical significance and prognosis are not well understood. We aimed to examine the risk of young adult-onset psychiatric disorders in individuals with an adolescent anxiety disorder, and identify stratifiers of risk of subsequent psychiatric disorders in this group. Methods Individuals from the Norwegian Mother, Father, and Child Cohort Study (MoBa) with linked health records and aged 18 or over as of the 31st December 2023 were included. Those diagnosed with any ICD-10 anxiety disorder when aged 10-17 years were defined as having an adolescent anxiety disorder (n=2107, controls n=47,582). Polygenic scores (PGS) for psychiatric and neurodevelopmental conditions were calculated using LDpred2. Anxiety, comorbidities, and parental psychiatric history were defined through linked ICD-10 diagnoses. Sex was defined through linked records. Individuals were defined as having a young adult-onset psychiatric disorder if they first received any new psychiatric diagnosis aged 18-24. Results Adolescent anxiety diagnosis was associated with increased risk of all adult-onset psychiatric disorders (HR= 2.33-8.65). Post-traumatic stress disorder PGS, parental history of severe mental illness, and female sex were associated with increased risk of transition to a young adult-onset psychiatric disorder in people with an adolescent anxiety disorder. Conclusions Adolescent anxiety greatly increases the risk of a psychiatric disorder during the transition to adult life. Clinicians should consider female sex and parental psychiatric history when prioritising young people with anxiety for adult mental health service support. Future research needs to further consider whether polygenic scores would aid risk stratification in clinical practice.

ObjectiveTo charactertise emergency department (ED) use among young people with bipolar disorder (BD) and compare patterns to those observed in anxiety, depressive, and psychotic disorders. Design, setting and participantsData linkage study using administrative ED presentation records (January 2020 to October 2020) and a transdiagnostic youth mental health cohort of 2243 individuals aged 12-30 years in New South Wales, Australia. Main outcome measuresED presentation patterns (any presentation, frequency, and rates) and reasons for presentation (mental health-related and non-mental health-related). ResultsOf the 354 young people with BD, 309 (87.3%) presented to an ED at least once. ED presentation rates were higher for BD than for anxiety (incidence rate ratio [IRR]=1.82, p<.001) and depressive disorders (IRR=1.32, p<.001), but similar to psychotic disorders (IRR=0.91, p=.379). Differences were primarily driven by mental health-related presentations. Recurrent mental health presentations were associated with illness progression (clinical stage and functional impairment) rather than diagnosis. However, the likelihood of mental health-related presentations remained higher in BD compared with anxiety and depressive disorders after adjustment. ConclusionsYoung people with BD have high rates of ED use, comparable to those with psychotic disorders. Although mental health-related presentations are more common in BD than in anxiety and depressive disorders, recurrence is largely explained by markers of illness progression. These findings highlight the need for community-based services that provide continuous and coordinated care for young people with complex mental health needs.

BackgroundMost studies seeking to identify youth at increased risk for depression have developed prediction models using a limited set of risk factors in general population samples. It is unclear whether these models generalize to high-risk youth. Here, we developed machine learning algorithms to predict first-onset depression in youth from the general population and high-risk youth with attention-deficit/hyperactivity disorder (ADHD). MethodsParticipants were 4803 unrelated children from the ABCD study with no prior mood disorder and complete data at baseline (age 9-10 years) and 2-year follow-up. Support Vector Machine, Random Forest, and Elastic Net models were used to predict first-onsets from clinically-relevant risk factors spanning mental and physical health, cognitive, dispositional, interpersonal, and socio-environmental domains. Predictive performance was evaluated in the full sample and separately in participants with ADHD (N=584, 12.16%). ResultsModels trained on the full sample achieved good discriminative predictive power (area under the curve [AUC]=0.70 and accuracy=0.70-0.82). Predictors that replicated across models included earlier pubertal development, higher behavioral inhibition and aggression, and more time spent passively watching media content. In the ADHD subsample, model performance declined (AUC=0.46-0.61) and predictors only partly overlapped with those identified in the full sample. ConclusionsModels effectively predicted depression in the general population but showed poor generalization to high-risk youth with ADHD, suggesting different risk factors in this group. These findings highlight that models trained in general population samples may not generalize to high-risk groups, pointing to the need for more tailored efforts to predict depression in youth at increased risk.

Background Treatment guidelines for borderline personality disorder (BPD) recommend assessment, diagnosis, and psychoeducation. We report on the feasibility and safety of a randomized controlled trial protocol of online psychoeducation, assessment, and personalized feedback as an immediate first step of care for BPD. Methods Newly diagnosed participants were randomized to receive 10 videos about BPD or general mental health for two weeks. Half the participants receiving BPD videos were randomized to receive personalized feedback on changes in symptom ratings and cognitive performance. Ecological momentary assessment (EMA) evaluated interpersonal interactions, emotions, and behaviors for 30 days. BPD symptoms, depression, and personality functioning were assessed at baseline, after videos, after feedback, and one month later. Results Eighty-two participants were randomized into three conditions that did not differ significantly in terms of demographics or baseline variables. Dropout occurred for 32.9% of the sample. No differences in rate of emergency room visits, hospitalizations, or other escalations in level of care were reported among groups. Satisfaction was higher for those receiving psychoeducational videos about BPD. Improvement in BPD knowledge in the psychoeducation conditions was significantly greater than the control condition. No statistically significant differences were found regarding reduction of BPD symptoms. The psychoeducation with feedback arm showed significantly greater improvements in self-impairment compared to controls with medium effect size at the final timepoint. Modeling of the relationship between time spent alone and BPD symptoms showed a positive correlation in the control condition, but in the group receiving both psychoeducation about BPD and feedback, this relationship was negative. Conclusion Online psychoeducational videos and assessment were safe, feasible, and acceptable to participants with newly diagnosed BPD. Psychoeducation with personalized feedback appears to be more effective than either BPD or general psychoeducation alone in improving deficits in self-functioning, which may relate to an increased capacity to be alone with fewer symptoms. The protocol was registered with ClinicalTrials.gov (NCT05358925, https://clinicaltrials.gov/study/NCT05358925) on April 28th, 2022.

Background: The incidence of antidepressant withdrawal reactions in longer-term users and the influence of dosage is insufficiently understood. Objectives: Informed by neuropharmacological models and user surveys, this study examined symptom change during tapering and if increases were specifically associated with reductions below 75% of the minimum effective dose. Design: This was a prospective longitudinal cohort study with seven assessments over six months. Methods: Altogether 32 Swiss adult primary care patients who were on antidepressants for at least six months and in stable remission were assessed at baseline (week 0) before they started tapering and after 2, 4, 6, 8, 16, and 26 weeks. Withdrawal symptoms were measured repeatedly using an adapted version of the Discontinuation-Emergent Signs and Symptoms Scale (DESS) and the main outcome was intra-individual symptom change during intervals. Antidepressant dose was standardized relative to the minimum effective dose in the treatment of depressive and anxiety disorders. Results: Across intervals, reductions below 75% of the minimum effective dose were associated with symptom increases, while reductions above that threshold or no reductions were associated with symptom decreases. After adjusting for potential confounders, the rate of clinically relevant symptom increases contingent on dose reductions below 75% of the minimum effective dose was 33%, as compared to 13% during intervals with no dose reductions (OR=3.2, 1.4 to 7.4). We thus estimated that 60% of the risk of clinically relevant symptom increases was attributable to pharmacological withdrawal effects. The adjusted incidence rates for clinically relevant and severe withdrawal reactions were 32% and 11%, respectively. Conclusions: Consistent with neuropharmacological research findings, we found that antidepressant withdrawal symptoms emerge mostly following reductions below 75% of the minimum effective dose, affecting about one-third of patients. Even small reductions may trigger clinically relevant withdrawal reactions in this lowest dose-range, stressing the need for personalized tapering plans.

Background: Participants in the ReINVEST randomised placebo-controlled trial of sertraline, conducted among men with high trait impulsivity and histories of violent offending, received structured clinical contact throughout the trial, including psychiatric assessments, nursing consultations, crisis support, and referrals to mental health and external services. We estimated the effect of placebo trial participation, compared with non-participation after baseline and single-blind run-in, on violent and domestic-violence reoffending. Methods: This prespecified secondary analysis included men from the ReINVEST trial pathway who completed baseline assessment and entered the single-blind run-in phase but did not proceed to randomisation, to inform the counterfactual. Violent and domestic-violence offences were identified from linked administrative records over 12- and 24-month follow-up periods. The adjusted difference in offending was estimated using two independent analytical approaches accounting for baseline differences. Additional analyses examined whether the effect varied by baseline clinical and criminal-history characteristics, whether pre-randomisation external referrals explained selection into placebo participation, and whether post-randomisation external referrals accounted for any part of the estimated effect. Results: Placebo trial participation was associated with lower offending across both outcome domains and follow-up periods. Placebo-standardised mean count differences for violent offending were -0.19 (95% confidence interval [CI] -0.38, -0.04) at 12 months and -0.22 (95% CI -0.51, -0.05) at 24 months. Corresponding differences for domestic-violence offending were -0.37 (95% CI -0.81, -0.14) at 12 months and -0.49 (95% CI -0.92, -0.22) at 24 months. The association was more apparent among men with a documented psychiatric history and, for domestic-violence offending, among those with higher baseline anger, irritability and aggression. Pre-randomisation referrals did not explain selection into placebo participation or materially alter the estimates. Post-randomisation referrals were observed in both groups, remained more common in the placebo group, and did not account for the observed association. Conclusion: Placebo participation in this trial involved sustained clinical contact and psychosocial support beyond exposure to inactive medication, and these non-pharmacological components may have contributed to lower reoffending. In placebo-controlled trials involving populations with high psychiatric morbidity and limited continuity of coordinated care, the clinical content of placebo participation should be explicitly characterised in trial design and interpretation.

Abstract Introduction: Over 30% of adults with Attention-Deficit/Hyperactivity Disorder (ADHD) show an insufficient response to standard pharmacological treatments, which underscores the need for evidence-based alternative interventions. Methods: In this sham-controlled study, 30 adult outpatients with ADHD were randomized to 12 weeks of active or sham transcranial direct current stimulation (tDCS) as add-on to a digital cognitive behavioral therapy application (dCBT app). Participants received either active (2 mA, 20 min/day, 5 days/week) or sham tDCS with anodal (left) and cathodal (right) stimulation applied over the dorsolateral prefrontal cortex (DLPFC). In parallel, access to the dCBT app was provided for three months. ADHD symptoms were measured before and after treatment and after a three-month follow-up using the Adult Self-Report Scale (ASRS v1.1). Results: All scales showed an improvement over time with medium-to-large within-subjects effects (Cohens d: -.48 to -.75), irrespective of group allocation. Two additional sensitivity analyses including (1) participants with over 75% of planned (sham)-tDCS sessions and (2) those who logged into the dCBT app on at least 5 days (median split) confirmed results. Response was observed in 1/15 (6.7%) of the tDCS group and 2/15 (13.3%) of the sham-tDCS group, with no difference between groups (p = .543, phi = -.111). Compliance to (sham-)tDCS was high. tDCS usability was rated marginally lower in the tDCS group. Conclusions: tDCS as an add-on therapy could not produce additional improvement in ADHS symptoms. The results are discussed in terms of contextual and patient-related aspects. ClinicalTrials.gov Identifier: NCT06766214.

Introduction: Youth mental health presentations are largely heterogenous, making it difficult to match individuals to the most appropriate interventions. Personalised, measurement-based care has the potential to improve clinical decision-making and support shared decision-making, but remains challenging to implement in routine practice. Advances in digital monitoring and causal modelling offer new opportunities to identify individual-level processes driving mental health difficulties and to generate personalised decision-support. This pilot study aims to evaluate the feasibility and acceptability of the Minding Your Mind computational decision-support approach, a newly developed approach integrating routine outcome monitoring, individual-level causal modelling, and personalised feedback to support shared decision-making between young people and their clinicians. Methods and analysis: The study involves two phases. Phase 1 will recruit young people aged 15-25 years and mental health clinicians to participate in workshops to co-design the decision-support approach and its implementation into routine practice. Phase 2 is a prospective, single-arm feasibility study involving young people receiving mental health care and their treating clinicians. Primary outcomes include feasibility, acceptability, appropriateness, and usability of the decision-support approach, assessed via self-report and objective process indicators. Secondary outcomes include changes in use and experiences with shared decision-making, and clinical and functional outcomes. Quantitative analyses will be primarily descriptive, with exploratory pre-post comparisons and sensitivity analyses. Qualitative interviews will explore user experiences and implementation barriers and facilitators. Ethics and dissemination: This study has been approved by the Sydney Local Health District (RPAH Zone) Human Research Ethics Committee (X25-0341). All participants will provide informed consent prior to participation. Findings will be disseminated through peer-reviewed publications, conference presentations, and accessible summaries co-developed with young people with lived experience.

Background: Dissociative experiences encompass a variety of discontinuities in awareness and perception that are elevated in the dissociative disorders and associated with extensive comorbid symptomatology. Accumulating evidence points to developmental trauma and trait responsiveness to verbal suggestions (REVS) as factors that confer risk for severe dissociative symptoms, but they have typically been studied in isolation. This study integrated these measures using prediction modelling to better understand their predictive value for the risk of dissociative psychopathology. Method: 1,104 non-clinical participants completed measures of trauma, dissociation and trait REVS. The predictive model was developed using elastic net logistic regression, internally validated with 10-fold cross-validation, and assessed using receiver operating characteristic (ROC) curve and area under the ROC (AUROC). Variables entered into the model were components of REVS, trauma, age, and their interactions. Results: A dissociative psychopathology at-risk group (7%) was characterised by younger age, greater trauma and elevated REVS, particularly involuntariness during cognitive-perceptual suggestions. The prediction model retained nine of ten predictors, with an AUROC of .77 [95% CI: .73, .82], reflecting good discrimination with moderate sensitivity (78%) but modest specificity (67%). Conclusions: These findings reinforce trauma and trait REVS as risk factors for dissociative psychopathology and demonstrate that they can be integrated in a model that can identify at-risk individuals. Further validation and extension of the model is necessary to improve the identification of individuals at risk for severe dissociative symptomatology and the diagnosis of dissociative disorders with implications for outcome trajectories.

BackgroundSuicide is one of the leading causes of death among adolescents. Suicidal thoughts and behaviors are significant risk factors for suicide, whilst depressive symptoms are significant risk factors for suicidal thoughts and behaviors. Multimodal school-based interventions that address these risk factors are considered the appropriate approach to suicide prevention. Method1,593 adolescents (aged 11-15 years) from 15 high schools in the Netherlands took part in the study, which was designed as a pragmatic cluster-randomized trial. The experimental condition consisted of (1) screening for depressive symptoms and suicidal thoughts and behaviors, followed by referral of those who scored positive; (2) gatekeeper training for school mentors; (3) a serious game to reduce stigma, promote health literacy and improve help seeking behavior; and (4) eight CBT-based sessions for adolescents with elevated depressive symptoms. The control group consisted of screening and the gatekeeper training. Both suicidal thoughts and behaviors and depressive symptoms were assessed at baseline, after 6 months and after 12-months follow-up. ResultsMultilevel mixed-model analysis revealed that, over the entire 12-month follow-up period, both suicidal thoughts and behaviors and depressive symptoms increased significantly in the experimental group, but not in the control group. No clinically relevant change was observed in either group. ConclusionsThe multimodal stepped-prevention program tested in the present study did not lead to a reduction in suicidal thoughts and behaviors or depressive symptoms. However, it is likely that the adverse impact of COVID-19-related school closures overwhelmed the programs effectiveness. Furthermore, few high-risk adolescents participated in the CBT-based sessions. Key Practitioner MessagesO_ST_ABSWhat is known?C_ST_ABSO_LISchool-based prevention programs aim to reduce suicidal thoughts, behaviors, and depressive symptoms among adolescents. C_LIO_LIMulti-modal interventions are increasingly promoted, but evidence of their effectiveness is limited under real-world conditions. C_LI What is new?O_LIThe multimodal stepped STORM program did not reduce STBs or depressive symptoms at 12-month follow-up; a small group-level increase was observed in the experimental group. C_LIO_LIParticipation in the indicated CBT-based module was low, revealing critical implementation gaps school programs. C_LI What is significant for clinical practice?O_LISchool-based programs should prioritize early identification with active referral, gatekeeper training. C_LIO_LIActive referral to a brief CBT-based intervention for high-risk students need to be implemented in close collaboration with both students and teachers to better assure its uptake C_LI

Abstract Background Gene dosage disorders impact cognition and psychopathology, but outcomes vary widely amongst carriers of the same variant. Recent work has sought to better predict proband outcomes using measures of corresponding traits in family members. However, family-based models have not yet been prospectively quantified across several traits in different genetic disorders, nor evaluated for the precision they afford: both crucial issues for clinical implementation. Methods In a first test case for these questions, we apply regression analyses to quantify and compare family-based prediction of 12 traits (including IQ, autism- and ADHD-related traits) in 433 individuals from families including a proband with XXY or XYY syndrome (N=93 and 58, respectively). Results The 12 traits vary substantially in their proband-family associations (0.001<|r|<0.55) - with differences emerging between XXY and XYY syndrome. Only two traits also show significant and similar proband-family associations in both aneuploidies, with the greatest concordance found for IQ. A family-based model for IQ prediction in male sex chromosome trisomies significantly reduces error vs. a group mean IQ model (F = 7.4, p = 0.006), but only in 65% of probands, and with mean error reduction of ~2 IQ points. Conclusions Family-based prediction of neuropsychiatric traits in genetic syndromes likely requires trait- and syndrome- specific models. Family models can significantly improve outcome prediction for IQ, but to variable degrees across individuals and with a small mean improvement. By mapping and quantifying these limits, our work helps draft a roadmap for refinement of family-based prediction of proband outcomes in gene dosage disorders.

Structured AbstractO_ST_ABSBackgroundC_ST_ABSPost-Traumatic Stress Disorder (PTSD) is a mental health condition affecting people who experience traumatic events. Trauma-exposed occupational groups report higher rates of PTSD than the general population. Current treatments, and access, often take months and may cause distress when people are required to talk about the trauma. ObjectiveTo determine the proof of concept of FIRST, a brief, non-trauma focussed therapy, in two separate populations with employment-associated PTSD. MethodTwo independent, single-arm, experimental therapy pilot trials were conducted. Trial one recruited 20 military veterans who received FIRST therapy via trained third-sector therapists. Trial two recruited 16 health and social care workers with FIRST therapy delivered by healthcare provider therapists. All participants were adults with PTSD (confirmed via CAPS-5 in trial one, and symptom score of [&ge;]33 on the PCL5 in trial two). Primary outcomes were recruitment feasibility, retention, data quality and reduction in PTSD symptoms. Secondary outcomes were anxiety and depression symptoms, daily life functioning and perceived health status. Veterans were followed up at 12 weeks post-enrolment and healthcare workers at 8 weeks. ResultsThe veteran trial progression criteria to main trial were met. Seventy-nine people screened eligible, 43 attended a CAPS-5 assessment; 20 had confirmed PTSD and were enrolled. Seventeen completed therapy and 12-week outcome measures. Mean PCL-5 scores decreased from 48.7 (SD = 13.02, n=20) at baseline to 23.5 (SD = 15.30, n=17) at 12-weeks. The healthcare worker trial obtained informed consent from 16 participants, 10 commenced therapy and were included in analysis with eight completing therapy. Mean PCL-5 scores decreased from 42.60 (12.23, (n=10) at baseline to 22.00 (19.92, n=8) at 8-weeks. ConclusionsProof of concept of FIRST was established. PTSD symptom reductions exceeded the PCL-5 minimal clinically important difference. Undertaking a fully powered randomised controlled trial of FIRST therapy is feasible within both healthcare and third sectors. HighlightsO_LIPost-traumatic stress disorder (PTSD) is more common in military veterans and health workers than the general population C_LIO_LITherapy can be challenging to commence and complete when it requires a focus on the trauma incident C_LIO_LIFIRST offers a promising, brief, non-trauma focused therapy for the treatment of PTSD C_LI

Objective: To test whether two brief mania measures, the Parent General Behavior Inventory-10 Mania form (PGBI-10M) and 7-Up, retain useful psychometric properties in a large population cohort, and to evaluate whether the PGBI-10M can identify Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS)-defined bipolar spectrum disorders in that setting. Method: Analyses used 11,000+ youths across late childhood and early adolescence from the Adolescent Brain Cognitive Development (ABCD) Study. For both PGBI-10M and 7-Up, we estimated descriptive statistics, internal consistency, confirmatory factor models, graded response models, and measurement-based care benchmarks (minimally important difference, reliable change, and clinical cutpoints). For the PGBI-10M, receiver operating characteristic (ROC) analyses estimated concurrent classification accuracy for bipolar diagnoses at baseline and 2-year follow-up and compared area under the curve (AUC) values with prior outpatient and community mental health samples. Results: Scores were lower than in clinical samples, but both measures remained psychometrically sound. The PGBI-10M showed alpha=.87-.88 and omega=.88; the 7-Up showed alpha=.78 and omega=.79. Longitudinal analyses indicated threshold differences across waves, likely reflecting caregiver recalibration and developmental changes, with modest impact on estimates. ABCD-based benchmarks supported meaningful and reliable change. The PGBI-10M discriminated bipolar cases (AUC=0.68 baseline; 0.77 follow-up), though performance was lower than in clinical samples. Positive predictive values were low in this population. Conclusion: The PGBI-10M and 7-Up support monitoring of manic and mixed symptoms, but the PGBI-10M alone is insufficient for universal bipolar screening. Brief mania scales are best used for targeted assessment and longitudinal monitoring within multi-informant workflows.

Aim: Schema Therapy (ST) is an evidence-based treatment for complex mental health problems rooted in early Adverse Childhood Experiences (ACEs). Although both individual and group formats have shown effectiveness, little is known about which format works best for whom. This question is particularly relevant for adolescents given their unique developmental needs. Despite over a decade of clinical experience with ST in adolescents, current research offers limited guidance on how to tailor the format to individual needs - resulting in a persistent gap between research and practice. This study aims to develop practice-based indication criteria for individual versus group schema therapy by integrating therapists expertise with experiences from adolescents who underwent ST. Methods: This qualitative study employs a constructivist Grounded Theory approach. Data will be gathered through focus group discussions with schema therapists and individual interviews with adolescents. Therapists will be purposively selected based on experience with both therapy formats and with traumatized adolescents. Adolescents are eligible if they have experienced ACEs and have completed at least 20 sessions of ST. Results: The analysis will result in a theoretical model that integrates therapists clinical reasoning and adolescents preferences. Conclusions: This study integrates schema therapists expertise and adolescents lived experiences to develop actionable indication criteria for choosing between individual and group ST. By supporting informed clinical decision-making, the findings contribute to treatment personalization in adolescent ST and address key challenges such as suboptimal outcomes and treatment dropout. Moreover, the identified criteria provide a foundation for future quantitative validation.

BackgroundA range of rare chromosomal micro-deletions or -duplications (Copy Number Variants - CNVs) are associated with high risk of neurodevelopmental and mental health conditions (ND-CNVs). There is great individual variability in outcomes, but we lack insights into the contributing social factors, including family functioning. MethodsCaregivers of 598 children and young people (CYP) with a range of 16 ND-CNVs and 222 siblings without ND-CNVs (controls) completed questionnaires on overall family climate (cohesion and conflict) as well as caregiver-CYP relationship warmth and hostility and took part in a research diagnostic interview about CYPs psychiatric symptoms. CYPs intelligence quotient (IQ) was also measured. ResultsComparisons with published data from neurotypical families indicated that families affected by ND-CNVs are characterised by higher family cohesion and conflict as well as lower caregiver-CYP warmth and hostility. Symptoms of oppositional defiant disorder reduced more steeply in CYP with ND-CNVs compared to controls with increasing family cohesion (interaction effect: {beta} = -0.14, p = 4.65 x 10-{superscript 2}). In contrast, they rose more steeply with increasing family conflict (interaction effect: {beta} = 0.18, p = 1.05 x 10-{superscript 2}). Furthermore, symptoms of mood disorder increased more steeply with increased caregiver-CYP hostility in CYP with ND-CNVs (interaction effect: {beta} = 0.15, p = 4.55 x 10-{superscript 2}). ConclusionsRaising a CYP with a rare genetic condition is challenging. Timely access to interventions that support caregivers in fostering a positive family environment may reduce behavioural difficulties in CYP, with subsequent benefits for family functioning.

Depression is accompanied by considerable comorbidity and excess mortality. We examined multimorbidity data using the validated pharmacy-based Rx-Risk Comorbidity Index and examined healthcare costs associated with chronic illness burden in the Australian Genetics of Depression Study (AGDS). Australian Pharmaceutical Benefits Scheme (PBS) record linkage for 15,890 AGDS participants was available from 01/07/2013-31/12/2017. Forty-six health morbidities were inferred by mapping the prescription data using Anatomical Therapeutic Chemical Classification System codes and PBS Item Codes. Morbidity prevalence rates were then compared with an unselected 10% Australian representative population sample (10PCT) with PBS claims data available from 01/07/2010-31/12/2014. The average number of inferred comorbidities was higher among AGDS participants (4.6 {+/-} 2.9) than 10PCT individuals (3.0 {+/-} 3.0). Excluding depression, 89.1% of AGDS participants had one or more inferred comorbidity, most commonly pain (51.0%), inflammation/pain (40.3%), and anxiety (32.3%). In the AGDS, the number of comorbidities was higher among women compared to men and positively correlated with participant age, BMI, number of depressive episodes experienced, and annual health care costs. Compared to participants with no inferred comorbidities, the median annual health care costs were ~65% higher among those with 2-3 comorbidities. This study highlights the patterns of health morbidities experienced by individuals living with depression and shows that this chronic disease burden is significantly associated with increased health costs to the individual and the health system.

Hoarding disorder (HD) affects approximately 2-3% of adults and is associated with substantial functional disability and limited access to evidence-based care. The aim of the current analysis was to examine the naturalistic effectiveness of therapist-delivered video cognitive-behavioral therapy (CBT) for HD in a large real-world sample, and to characterize individual-level treatment response, time-to-response, and moderators of outcome. This retrospective, observational analysis examined clinical data from 305 adults diagnosed with HD who received therapist-delivered video CBT through an online specialty therapy platform between September 2021 and February 2026. Hoarding symptom severity was assessed using the Hoarding Rating Scale-Self Report (HRS-SR). Linear mixed models examined symptom change from baseline to three timepoints: session 10, session 20, and each patient's final session. HRS-SR scores decreased from M = 22.4 (SD = 7.6) at baseline to M = 16.4 (SD = 8.2) at final session (Hedges' g = 0.81, 95% CI: 0.68-0.94). By the final session, median percent improvement was 25.0% [IQR: 3.0-46.7%]. A total of 39.3% of patients achieved [&ge;]35% HRS-SR reduction, 27.4% of patients who began above the clinical threshold achieved remission, 36.4% demonstrated reliable improvement, and 22.9% of eligible patients achieved clinically significant change. Among patients who achieved and maintained [&ge;]35% reduction through their final session (n = 120), median time to first response was session 9, with 54.2% responding within 10 sessions. Analyses of secondary outcomes showed significant improvements in clutter severity, depressive and anxiety symptoms, stress, quality of life, and functional disability (Hedges' g = 0.21-0.47). Greater baseline severity, more sessions, and longer treatment duration significantly moderated outcomes; prior OCD treatment history did not. Findings suggest that therapist-delivered video CBT for HD, delivered remotely in a real-world setting, produces outcomes consistent with controlled trials and may be a clinically effective and scalable approach for a condition historically underserved by mental health systems.

Background. Lifetime exposure to trauma is associated with chronic pain. Separate studies of chronic pain and trauma report overlapping alterations in white matter microstructure, yet their distinct and cumulative effects remain unclear. Methods. White matter microstructure (fractional anisotropy [FA] and mean diffusivity [MD]) from the UK Biobank (N = 21,995) were analysed using linear mixed-effects models. First, group effects (chronic pain versus control) on white matter integrity within this cohort were established. To investigate distinct and cumulative impacts of trauma exposure at different developmental stages, main and interactive effects of group and trauma severity on FA and MD were examined in separate groups exposed to childhood maltreatment only, adulthood trauma only, and both. Sex-stratified analyses were conducted. Results. Chronic pain was associated with widespread alterations and was spatially refined to brainstem tracts and cingulum when accounting for maltreatment/trauma severity. Accounting for chronic pain, cumulative trauma severity was associated with alterations in brainstem, frontal and parietal tracts, whereas adulthood trauma showed comparable but attenuated patterns. Childhood maltreatment severity was associated with localised FA and MD reductions in brainstem tracts, sagittal stratum and superior longitudinal fasciculus. These effects were more pronounced in females than males. A chronic pain-by-maltreatment/trauma severity interaction was observed for FA in the superior cerebellar peduncle in females exposed to childhood maltreatment only. Conclusions. Distinct and interactive effects of chronic pain and maltreatment/trauma severity on white matter microstructure were evident. The findings suggest that trauma-informed care should be tailored by timing of exposure and sex in this population.

Objective: Biopsychosocial models recognize multiple determinants of post-trauma mental disorders, but their relative and interactive effects remain unclear. We quantified the independent contribution of traumatic event severity, preexisting vulnerability, social support, and coping capacity, and tested mediation pathways. Methods: In a Brazilian clinical sample reporting traumatic or stressful events (N = 612), constructs were operationalized as composite scores and a dichotomous clinical outcome was derived from intake assessments. Logistic regression (n = 594) and structural equation modeling evaluated prediction and mediation. Results: Vulnerability was the strongest risk factor (OR = 1.46, p < .001) and social support the main protective factor (OR = 0.60, p < .001). Traumatic event severity remained an independent predictor (OR = 1.39, p < .001), whereas coping capacity was not significant (OR = 0.94, p = .410). Discrimination was good (AUC = 0.80). Mediation indicated vulnerability reduced social support and coping capacity, with a significant indirect effect via social support. Conclusions: Findings support a multifactorial model centered on a triad of vulnerability, social support, and traumatic exposure. Risk is shaped primarily by preexisting vulnerability and relational context, alongside a direct trauma effect, providing a clinically relevant framework for assessment and intervention.

Mental illness poses a substantial global burden, yet existing psychotherapies and psychopharmacologies often produce limited outcomes. Psychedelic assisted therapies have emerged as potential transdiagnostic interventions. In particular, 3,4 methylenedioxymethamphetamine assisted therapy (MDMA AT) has generated interest for its rapid psychological effects and potential to enhance psychotherapy outcomes. However, the incremental efficacy of MDMA AT relative to control interventions across transdiagnostic outcomes remains unclear. Further, there have been emerging concerns regarding harm reporting quality in MDMA AT clinical trials. We conducted a systematic review and meta analysis of MDMA AT randomized controlled trials. Eleven publications representing eight controlled trials with 10 analyzed subgroups (n = 295 participants) were included in meta-analyses. Two additional secondary publications were included for harm reporting syntheses (k = 13 total). Across 114 extracted effect sizes, MDMA AT demonstrated a significant moderate-to-large incremental reduction in psychopathology relative to controls (g = 1.03, 95% CI [0.46, 1.60]), though heterogeneity was high (I squared = 76%). Incremental effects were larger versus inert placebos (g = 1.27) than active controls (g = 0.75). Symptom specific analyses indicated strong incremental effects for trauma reduction (g=1.46 [95% CI: 0.67, 2.25]) and smaller non-significant effects for depression (g=0.51 [95% CI: -0.06, 1.08]). Harm reporting quality synthesis showed only 23% of publications met high-quality reporting standards. Overall, MDMA AT demonstrates potential transdiagnostic efficacy, but small samples, confounding factors, and mediocre harm reporting highlight the need for larger more transparent clinical trials.